Risk stratification for acute coronary syndrome by determining copeptin
AssigneeB.R.A.H.M.S GmbH
InventorsAndreas Bergmann, Nils Morgenthaler, Jana Papassotiriou, Joachim Struck, Leong L. Ng
Life of this patent
Estimating the term…
Abstract
The invention relates to a method for risk stratification for acute coronary syndrome (ACS), in particular acute myocardial infarction (AMI) and angina pectoris (AP), wherein provasopressin (proAVP) or fragments and partial peptides thereof, in particular copeptin or neurophysin II, is determined by an in vitro diagnosis.
Claims13
A method for risk stratification of acute coronary syndrome, comprising determining the level of copeptin in at least one sample from a patient, wherein a threshold level of copeptin of 10-30 pmol/L in said at least one sample indicates an increased risk of or an unfavorable prognosis of acute coronary syndrome for said patient.
A method for diagnosis of acute coronary syndrome, comprising determining the level of copeptin in at least one sample from a patient, wherein a threshold level of copeptin of 6-20 pmol/L in said at least one sample indicates the presence in said patient of acute coronary syndrome.
Dependencies are inferred from the claim text.